Lonza Group AG (LONN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Lonza Group AG (LONN)
Company Performance

Current Price

as of Oct 16, 2024

$621.43

P/E Ratio

65.64

Market Cap

$44.62B

Description

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Metrics

Overview

  • HQBasel, BS
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerLONN
  • Price$621.433542-0.37%

Trading Information

  • Market Cap$44.62B
  • Float96.96%
  • Average Daily Volume (1m)131,767
  • Average Daily Volume (3m)156,258
  • EPS$8.88

Company

  • Revenue$6.72B
  • Rev Growth (1yr)7.94%
  • Net Income$654.00M
  • Gross Margin27.04%
  • EBITDA Margin21.96%
  • EBITDA$1.48B
  • EV$27.59B
  • EV/Revenue4.11
  • P/E65.64
  • P/S5.51
  • P/B3.94